Galera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.
The last earnings update was 18 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Galera Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Galera Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Galera Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Galera Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Galera Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Galera Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Galera Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Galera Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Galera Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Galera Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. J. Mel Sorensen, M.D., serves as the Chief Executive Officer and President of Galera Therapeutics, Inc since 2012. Dr. Sorensen was the Chief Executive Officer, President, Director and Chairman of Ascenta Shanghai R&D Center at Ascenta Therapeutics Inc., since joining in August 2004. He is a highly experienced leader and administrator in cancer therapeutics and cancer drug development. Trained as a medical oncologist, he has dedicated his career to clinical cancer research and cancer drug development. He spent seven years at the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP). At CTEP, he managed collaborations between companies developing new anti-cancer agents and academic clinics and clinical cooperative groups. He had responsibility for over 40 research compounds. Following NCI, Dr. Sorensen worked nearly eight years at large pharmaceutical companies in leadership roles in oncology clinical development and medical affairs. He established Bayer's first clinical oncology department and oversaw multiple clinical trials (Phase 1, 2 and 3) of novel agents. He joined GlaxoSmithKline (GSK) as Vice-President, Global Leader and North American Head of Clinical Development and Medical Affairs for Oncology, where he recruited a large team of physicians and scientists and led global clinical development of chemotherapeutic agents. He serves as the Chairman of OncoFusion Therapeutics Inc. In addition to OncoFusion, and Galera. Dr. Sorensen serves as on the board of Therasis as its Chairman, a private cancer systems biology company. He serves as a Director of Galera Therapeutics, Inc since 2012. Dr. Sorensen serves as a Director of Ascenta Therapeutics Inc. He served as a Director of Lixte Biotechnology Holdings, Inc. since October 7, 2008 until April 16, 2014. He completed oncology fellowship at the Mayo Clinic, Rochester, MN in 1988.
Insufficient data for J. to compare compensation growth.
J.'s remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Galera Therapeutics management team is about average.
CEO, President & Director
Co-Founder & COO
Chief Medical Officer
Chief Business Officer
Chief Financial Officer
Chief Accounting Officer
Chief Scientific Officer
Director of Business Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Galera Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Independent Chairman of the Board
CEO, President & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Galera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis. It is also involved in developing GC4711, which is in Phase I clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is based in Malvern, Pennsylvania.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.